Publications
Detailed Information
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Young-Kwang | - |
dc.contributor.author | Kim, Hwang-Phill | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Hur, Hyung-Seok | - |
dc.contributor.author | Oh, Do Youn | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Tae-You | - |
dc.date.accessioned | 2012-05-24T02:06:17Z | - |
dc.date.available | 2012-05-24T02:06:17Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2009-09 | - |
dc.identifier.citation | Molecular Cancer Therapeutics, Vol.8 No.9, pp.2526-2536 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.other | 119454 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76384 | - |
dc.description.abstract | EGFR tyrosine kinase inhibitors have shown promising efficacy in the treatment of tumors with EGFR mutations and amplifications. However, tyrosine kinase inhibitors have also proven ineffective against most tumors with EGFR wild-type (WT) alleles. Although some genetic changes, including the KRAS mutation, have been shown to confer resistance to tyrosine kinase inhibitors, novel strategies for the treatment of cancer patients with tumors harboring EGFR WT alleles have yet to be thoroughly delineated. The principal objective of this study was to improve our current understanding of drug interactions between EGFR and MAP/ERK kinase (MEK) inhibitors in an effort to gain insight into a novel therapeutic strategy against EGFR WT tumors. Using a panel of human EGFR WT gastric cancer cell lines, we showed that gastric cancer cells harboring the KRAS mutation were selectively sensitive to MEK inhibition as compared with those cells harboring KRAS and PI3K mutations and KRAS WT alleles. However, all cell lines were found to be resistant to EGFR inhibition. The results from Western blots and phosphoprotein arrays showed that, in MEK inhibitor resistant cell lines, AKT was activated through the EGFR/HER3/PI3K pathway following AZD6244 (ARRY-142886) treatment. Blockade of this feedback mechanism through the targeting of MEK and EGFR resulted in detectable synergistic effects in some cell lines in vitro and in vivo. Our results provide the basis for a rational combination strategy against human EGFR WT gastric cancers, predicated on the understanding of cross-talk between the MEK and EGFR pathways. [Mol Cancer Ther 2009;8(9):2526-36] | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | American Association for Cancer Research | - |
dc.title | Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-09-0300 | - |
dc.citation.journaltitle | Molecular Cancer Therapeutics | - |
dc.description.citedreference | Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389 | - |
dc.description.citedreference | Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223 | - |
dc.description.citedreference | Friday BB, 2008, CANCER RES, V68, P6145, DOI 10.1158/0008-5472.CAN-08-1430 | - |
dc.description.citedreference | Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956 | - |
dc.description.citedreference | Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229 | - |
dc.description.citedreference | Kim HP, 2008, MOL CANCER THER, V7, P607, DOI 10.1158/1535-7163.MCT-07-2068 | - |
dc.description.citedreference | Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105 | - |
dc.description.citedreference | Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358 | - |
dc.description.citedreference | DEREYNIES A, 2008, J CLIN ONCOL, V26, P2228 | - |
dc.description.citedreference | DEREYNIES A, 2008, J CLIN ONCOL, V26, P2230 | - |
dc.description.citedreference | Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907 | - |
dc.description.citedreference | Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316 | - |
dc.description.citedreference | Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315 | - |
dc.description.citedreference | Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294 | - |
dc.description.citedreference | Mellinghoff I, 2007, PLOS MED, V4, P1620, DOI 10.1371/journal.pmed.0040321 | - |
dc.description.citedreference | Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077 | - |
dc.description.citedreference | Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975 | - |
dc.description.citedreference | Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150 | - |
dc.description.citedreference | Jimeno A, 2007, MOL CANCER THER, V6, P1079, DOI 10.1158/1535-7163.MCT-06-0448 | - |
dc.description.citedreference | CRAGG MS, 2007, PLOS MED, V4, P1690 | - |
dc.description.citedreference | COSTA DB, 2007, PLOS MED, V4, P1680, DOI DOI 10.1371/JOURNAL.PMED.0040315 | - |
dc.description.citedreference | Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558 | - |
dc.description.citedreference | Edkins S, 2006, CANCER BIOL THER, V5, P928 | - |
dc.description.citedreference | Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103 | - |
dc.description.citedreference | Downward J, 2006, NATURE, V439, P274, DOI 10.1038/439274a | - |
dc.description.citedreference | Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001 | - |
dc.description.citedreference | Krause DS, 2005, NEW ENGL J MED, V353, P172 | - |
dc.description.citedreference | Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388 | - |
dc.description.citedreference | Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073 | - |
dc.description.citedreference | Kobayashi S, 2005, NEW ENGL J MED, V352, P786 | - |
dc.description.citedreference | KU JL, 2005, CANC RES TREAT, V37, P1 | - |
dc.description.citedreference | Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017 | - |
dc.description.citedreference | Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008 | - |
dc.description.citedreference | Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b | - |
dc.description.citedreference | Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101 | - |
dc.description.citedreference | Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051 | - |
dc.description.citedreference | Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314 | - |
dc.description.citedreference | Lynch TJ, 2004, NEW ENGL J MED, V350, P2129 | - |
dc.description.citedreference | Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360 | - |
dc.description.citedreference | Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502 | - |
dc.description.citedreference | Singer G, 2003, J NATL CANCER I, V95, P484 | - |
dc.description.citedreference | Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969 | - |
dc.description.citedreference | Weinstein IB, 2002, SCIENCE, V297, P63 | - |
dc.description.citedreference | Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200 | - |
dc.description.citedreference | PARK JG, 2002, GAN TO KAGAKU RYO S1, V29, P89 | - |
dc.description.citedreference | Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091 | - |
dc.description.citedreference | Peeper DS, 1997, NATURE, V386, P177 | - |
dc.description.tc | 14 | - |
dc.identifier.wosid | 000269968900005 | - |
dc.identifier.scopusid | 2-s2.0-70349513280 | - |
dc.citation.endpage | 2536 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 2526 | - |
dc.citation.volume | 8 | - |
dc.identifier.sci | 000269968900005 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Oh, Do Youn | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | PROTEIN-KINASE | - |
dc.subject.keywordPlus | ONCOGENE ADDICTION | - |
dc.subject.keywordPlus | TYROSINE KINASES | - |
dc.subject.keywordPlus | ACHILLES HEAL | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | RAS | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.